

In the Specification

Page 16, lines 3-15, rewrite as follows:

A. **AntiTryp-FWD** (32-mer with 20 bases complementary to starting template) SEQ ID NO: 1

5' CTC GAG AAG AGA **GAG GAT CCC CAG GGA GAT GC** 3'

Xho I lys arg -----antitrypsin (mature peptide) ----->

MW = 9957.3 D

Concentration = 1 µg/µl

Total Yield = 78.4 µg

B. **AntiTryp-REV (a.k.a. AntiTryp 2:** 32-mer with 24 bases complementary to starting template) SEQ ID NO: 2

5' GC GGC CGC TTA TTT TTG GGT GGG ATT ~~CAC CAC~~ GAG GAG 3'

Not I stop <-----antitrypsin (mature peptide) -----

MW = 9236.06 D

Concentration = 0.284 µg/µl

Total Yield = 71.0 µg

Page 17, lines 3-20, rewrite as follows:

A. **Sequencing Strategy:**

T7 Seq. Primer --->	FWD1 ----->	FWD2 ---->	FWD3 ----->	
5'	1		1	3'
pcDNA3.1/GS-TOPO/alpha-1-Antitrypsin			sense strand ---->	
<---- REV1		<---REV2	<---REV3	<----BGH Reverse Seq. Primer

B. **Sequence Analysis:**

The sequencing gels are run overnight and the analysis is done by computer. The Chromatograms are reviewed in detail and any ambiguities are resolved with the help of Omiga and Sequencher sequence analysis software. The sequence of the primer is shown In Table 1:

TABLE 1

	<u>Position</u>	<u>Tm</u>	<u>Length</u>	<u>SEQ ID NO</u>
AntiTryp Fwd. 1: CAGAAGACAGATACATCCCACCAT	35	61.489	24	<u>3</u>
AntiTryp Rev 1: AGGATTTTCATCGTGAGTGTCAG	240	59.212	22	<u>4</u>
AntiTryp Fwd 2: TACTCAAGGGAAAATTGTGGATTT	502	60.108	24	<u>5</u>
AntiTryp Rev 2: AGCTTCTTACAGTGCTGGATGTTA	714	59.517	24	<u>6</u>
AntiTryp Fwd 3: GTTCAACAAACCCTTTGTCTTCTT	1105	99.54	24	<u>7</u>
AntiTryp Rev 3: GGGAGACTTGGTATTTTGTTCAT	1156	59.670	24	<u>8</u>